Management of adult idiopathic thrombocytopenic purpura
- PMID: 15660520
- DOI: 10.1146/annurev.med.56.082103.104644
Management of adult idiopathic thrombocytopenic purpura
Abstract
Idiopathic thrombocytopenic purpura (ITP) is a common hematologic disorder manifested by immune-mediated thrombocytopenia. The diagnosis remains one of exclusion, after other thrombocytopenic disorders are ruled out based on history, physical examination, and laboratory evaluation. The goal of treatment is to raise the platelet count into a hemostatically safe range. The disorder is usually chronic, although there is considerable variation in the clinical course and most patients eventually attain safe platelet counts off treatment. However, a subset of patients has severe disease refractory to all treatment modalities, which is associated with considerable morbidity and mortality. This article focuses on the management of primary ITP in adults. We discuss criteria for treatment, the roles of splenectomy and other treatment options along with their side effects, and the management of ITP during pregnancy.
Similar articles
-
[Immune thrombocytopenic purpura (ITP)].Orv Hetil. 2001 Dec 9;142(49):2723-30. Orv Hetil. 2001. PMID: 11883173 Review. Hungarian.
-
Current options for the treatment of idiopathic thrombocytopenic purpura.Semin Hematol. 2007 Oct;44(4 Suppl 5):S12-23. doi: 10.1053/j.seminhematol.2007.11.003. Semin Hematol. 2007. PMID: 18096468 Review.
-
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.Am J Hematol. 2005 Apr;78(4):275-80. doi: 10.1002/ajh.20276. Am J Hematol. 2005. PMID: 15795920
-
The effect of platelet autoantibodies on the course of the disease and clinical response of patients with idiopathic thrombocytopenic purpura.Int J Lab Hematol. 2008 Feb;30(1):58-64. doi: 10.1111/j.1751-553X.2007.00902.x. Int J Lab Hematol. 2008. PMID: 18190469
-
Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production.Hematol Oncol Clin North Am. 2009 Dec;23(6):1163-75. doi: 10.1016/j.hoc.2009.08.008. Hematol Oncol Clin North Am. 2009. PMID: 19932426 Review.
Cited by
-
A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.Int J Hematol. 2009 Sep;90(2):157-165. doi: 10.1007/s12185-009-0361-y. Epub 2009 Jun 20. Int J Hematol. 2009. PMID: 19543952 Clinical Trial.
-
Single course of high dose dexamethasone is more effective than conventional prednisolone therapy in the treatment of primary newly diagnosed immune thrombocytopenia.Daru. 2012 Aug 28;20(1):7. doi: 10.1186/2008-2231-20-7. Daru. 2012. PMID: 23351609 Free PMC article.
-
Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.Haematologica. 2013 Jun;98(6):875-80. doi: 10.3324/haematol.2012.075648. Epub 2012 Nov 9. Haematologica. 2013. PMID: 23144195 Free PMC article.
-
Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers.Cochrane Database Syst Rev. 2021 Dec 9;12(12):CD011059. doi: 10.1002/14651858.CD011059.pub4. Cochrane Database Syst Rev. 2021. PMID: 34881425 Free PMC article.
-
Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006-2012.Vasc Health Risk Manag. 2017 Jan 20;13:15-21. doi: 10.2147/VHRM.S123631. eCollection 2017. Vasc Health Risk Manag. 2017. PMID: 28176930 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources